S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Forecast & News

$1.27
0.00 (0.00 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$1.23
Now: $1.27
$1.29
50-Day Range
$0.76
MA: $1.34
$1.72
52-Week Range
$0.70
Now: $1.27
$4.00
Volume708,784 shs
Average Volume975,339 shs
Market Capitalization$102.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Read More
AcelRx Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 million
Book Value($0.52) per share

Profitability

Net Income$-53,240,000.00
Net Margins-2,325.91%

Miscellaneous

Employees61
Market Cap$102.12 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.


AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACRX shares have increased by 4.1% and is now trading at $1.27. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AcelRx Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AcelRx Pharmaceuticals.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for AcelRx Pharmaceuticals.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) posted its earnings results on Monday, March, 16th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The specialty pharmaceutical company earned $0.48 million during the quarter, compared to analyst estimates of $1.23 million. View AcelRx Pharmaceuticals' earnings history.

What guidance has AcelRx Pharmaceuticals issued on next quarter's earnings?

AcelRx Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.82 million.

What price target have analysts set for ACRX?

4 brokers have issued twelve-month target prices for AcelRx Pharmaceuticals' stock. Their forecasts range from $2.00 to $10.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $6.38 in the next year. This suggests a possible upside of 402.0% from the stock's current price. View analysts' price targets for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (3/27/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We are not at all dismayed by the relatively small revenues since there is no stocking for this direct shipment product and hospital formularies barely had an opportunity to meet during these five weeks. Management did note that among the five hospital formularies that did meet, all five have approved Dsuvia. Presently, the company knows of 41 more meetings by midyear. If approved, it will still take weeks to months for AcelRx’s Dsuvia reps to find time with these busy hospital/ASC healthcare practitioners (HCPs), REMS training to be completed (relatively brief however) and the product to be stocked. As many investors know, hospital launches are notoriously slow. However, the early signals are ahead of our expectations." (5/9/2019)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

News articles about ACRX stock have been trending negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAcelRx Pharmaceuticals.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a drop in short interest in March. As of March 13th, there was short interest totaling 11,344,100 shares, a drop of 5.8% from the February 27th total of 12,040,000 shares. Based on an average trading volume of 909,800 shares, the short-interest ratio is currently 12.5 days. Currently, 14.6% of the company's shares are short sold. View AcelRx Pharmaceuticals' Current Options Chain.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Novavax (NVAX), Amicus Therapeutics (FOLD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX), Cyberark Software (CYBR), Fitbit (FIT) and Synergy Pharmaceuticals (SGYP).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (1.74%), Geode Capital Management LLC (1.37%), Cornerstone Capital Inc. (0.62%), Nuveen Asset Management LLC (0.53%), Marshall Wace LLP (0.23%) and UBS Group AG (0.16%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View institutional ownership trends for AcelRx Pharmaceuticals.

Which institutional investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cedar Wealth Management LLC, New York State Common Retirement Fund, Mercer Global Advisors Inc. ADV, State Street Corp, and Lincoln Capital Corp. View insider buying and selling activity for AcelRx Pharmaceuticals.

Which institutional investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Marshall Wace LLP, Geode Capital Management LLC, Ahrens Investment Partners LLC, California Public Employees Retirement System, Cornerstone Capital Inc., UBS Group AG, and Barclays PLC. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian, and Vincent J Angotti. View insider buying and selling activity for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.27.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $102.12 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe. View additional information about AcelRx Pharmaceuticals.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com/.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  440 (Thanks for Voting!)
Underperform Votes:  380 (Thanks for Voting!)
Total Votes:  820
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel